A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
The 2-nitroimidazole hypoxic cell radiosensitizer Ro-03-8799 has been suggested to have possible advantages over misonidazole with regard both to radiosensitization and toxicity on the basis of reported experimental work. The present work reports a Phase I escalating dose toxicity study of the drug. This has shown severe acute central neurotoxicity at high dose levels (greater than 1 g/m2). Initial results of a multiple-dose toxicity study indicate that 1 g/m2 is likely to be the maximum dose which may be given repeatedly. The plasma and tumor pharmacokinetics of the drug have been measured. The mean t 1/2 for 9 patients was 5.8 +/- 1.5 hr. Peak plasma concentration is linearly related to dose and at 1 g/m2 is 12.1 +/- 2.3 micrograms/ml (n = 6). Human tumor drug concentrations have been measured after single doses of 1 g/m2 given to 8 patients with a variety of tumors. Peak tumor concentrations of drug of 11.7-81.6 micrograms/g were found. Because of acute, dose-limiting toxicity related to individual doses it may not be possible to achieve, in human tumors, concentrations of drug that offer significant advantage over misonidazole in terms of radiosensitizing efficiency. No evidence of chronic cumulative toxicity was observed at the doses employed.
D004341:Drug Evaluation; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000378:metabolism; D009593:Nitroimidazoles / Q000097:blood / Q000378:metabolism / Q000633:toxicity*; D011838:Radiation-Sensitizing Agents / Q000097:blood / Q000378:metabolism / Q000633:toxicity*; D013997:Time Factors
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C033815:pimonidazole